SPEECH-PROCESSING-SOLUTI
27.9.2016 09:06:23 CEST | Business Wire | Press release
Speech Processing Solutions , the world number 1 for professional dictation solutions , is proud to announce very positive feedback on its latest voice recorder, the Philips SpeechAir, and the SpeechLive cloud solution, which now also offers speech recognition.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160927005172/en/
Both SpeechAir and SpeechLive are ideally suited to professionals who are often on the move and do not always work from their usual office workplace. Ingo Bischof, MBA, Managing Director of IVAM Real Estate, is delighted with the advantages of these two solutions: "With Philips dictation solutions it is possible for us to log and record issues in the properties that we maintain significantly more quickly. The recordings are then sent to our back office, saving us a considerable amount of time, as transcription can begin before we return to the office."
Exceptional recording quality and intuitive slide switch recording control
The SpeechAir is equipped with three professional-quality microphones providing ultimate sound quality in any recording situation . Background noise is filtered and the voices are recorded in perfect quality. This ensures excellent playback and speech recognition results. At the start of the year, the SpeechAir was awarded Nuance Communications' rating for best recording accuracy . The slide switch provides an efficient and intuitive user interface operated with just one hand. Recordings can be started, paused, stopped, played back, rewound and fast-forwarded using the slide switch .
Stay connected with the Wi-Fi and Bluetooth functions
The Wi-Fi and Bluetooth connections allow wireless transfer of finished recordings and access to the customer's data in the respective document management system, email or calendar. Dr Doris Ulreich-Laussermayer, a doctor in obstetrics and gynaecology, appreciates this function. "I can send additions to the PC in the medical practice via Wi-Fi on the move or from home and my assistant can edit them. Another thing that I especially like about SpeechAir is its portability, as I can move freely around the practice. The SpeechAir's antimicrobial surface is another positive aspect for hygiene in my medical practice," says the doctor.
SpeechLive speech recognition – speak, send, receive the finished document
The Philips SpeechLive cloud dictation solution now includes speech recognition available in 21 languages. Spoken words are converted into a written text in next to no time. SpeechLive can be used at any time and is easily accessible via any web browser with no software installation required. "Our company is split between two different locations. Last week I was working in the office in Melbourne; this week I am outside of the city in Mount Waverley. It's great to be able to work from anywhere, without having to think about taking something with me. I can sign in from any computer," raves Nicole Honan, Office Manager at the law firm Hicks Oakley Chessell Williams in Australia.
For more information about our solutions visit:
About Speech Processing Solutions
Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir , the Philips Pocket Memo voice recorder , the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the newest innovation, Philips SpeechLive , dictations and recordings will become faster and easier than ever before with cloud-based workflow services. Speech Processing Solution's perfectly tailored offers and products help professionals save time and resources and maximize efficiency.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Instagram: https://www.instagram.com/philips_dictation/
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20160927005172/en/
Contact:
Speech Processing Solutions
Christina Angerer
christina.angerer@speech.com
Tel:
+43 1605 291 488
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom